Staff Members - Benha University
Assessment of Macular Function by Multifocal Electroretinogram after Intravitreal Injection of Bevacizumab in Diabetic Macular Edema
• 2016
Publication Information
Authors
Yomna Essam1, Khalid Ali2, Ahmed Elhusseiny3, Soha Moussa4
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Purpose: To evaluate intravitreal Bevacizumab (IVB) in treatment of diabetic macular edema (DME) using Multifocal
Electroretinogram (Mf-ERG). Methods: Twenty eyes of sixteen patients with diffuse and/or focal DME without macular ischemia
received primary IVB (1.25 mg /0.1 ml). Multifocal electroretinography was done as baseline, 1 week, 2 weeks and 3 weeks post
injection. Results: Mean visual acuity improved from (0.37±0.23) to (0.42±0.30), 25% of patients reported near vision improvement.
Central foveal thickness improved significantly from (375.80±14.48 micrometer (μm)) to (225.0±30.08 μm) and parafoveal and
perifoveal thickness improved from (317.00±36.2 μm) to (282.80±27.97 μm). At the end of the 3rd week, P wave amplitude improved
from (34.64±9.62 nanovolt per square degree (nV/deg2)) to (44.54±8.32 nV/deg2), N wave amplitude improved from (0.135±0.060
nV/deg2) to (0.299±0.160 nV/deg2). Conclusion: Intravitreal Bevacizumab resulted in macular function improvement in the study patients
with DME, postoperative improvement in visual acuity and decreased retinal thickness confirmed by improvement of P wave and N wave
in Mf-ERG.
Electroretinogram (Mf-ERG). Methods: Twenty eyes of sixteen patients with diffuse and/or focal DME without macular ischemia
received primary IVB (1.25 mg /0.1 ml). Multifocal electroretinography was done as baseline, 1 week, 2 weeks and 3 weeks post
injection. Results: Mean visual acuity improved from (0.37±0.23) to (0.42±0.30), 25% of patients reported near vision improvement.
Central foveal thickness improved significantly from (375.80±14.48 micrometer (μm)) to (225.0±30.08 μm) and parafoveal and
perifoveal thickness improved from (317.00±36.2 μm) to (282.80±27.97 μm). At the end of the 3rd week, P wave amplitude improved
from (34.64±9.62 nanovolt per square degree (nV/deg2)) to (44.54±8.32 nV/deg2), N wave amplitude improved from (0.135±0.060
nV/deg2) to (0.299±0.160 nV/deg2). Conclusion: Intravitreal Bevacizumab resulted in macular function improvement in the study patients
with DME, postoperative improvement in visual acuity and decreased retinal thickness confirmed by improvement of P wave and N wave
in Mf-ERG.